Sloning BioTechnology starting feasibility study to improve the efficiency of an enzyme used in molecular diagnostic application
Sloning will use its Slonomics(TM) industrial scale gene synthesis technology to provide a gene library with a full set of ratio-controlled mutants. The successful completion of the study shall enable bioMérieux to identify an enzyme with significantly enhanced characteristics.
"We are very excited about this collaboration. It gives Sloning the opportunity to demonstrate the capabilities of our enabling technology in the field of protein engineering and synthetic biology and in this particular case with a significant commercial impact to our customer." stated Dr. Heinz Schwer, the company CEO.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.